Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

Background: Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy...

Full description

Bibliographic Details
Main Authors: Susanne Crocamo, Renata Binato, Bruno de Paula, Giselle Vignal, Lídia Magalhães, Roberta Sarmento, Maria Theresa Accioly, Isabele Small, Sandra Gioia, Pedro Maroun, Pamela Moutinho, Vivianne Freitas, Karuline Catein, Eliana Abdelhay
Format: Article
Language:English
Published: SAGE Publishing 2019-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835919853971

Internet

https://doi.org/10.1177/1758835919853971

Similar Items